Home » Features » Health » Diabetes



About Diabetes

Diabetes is a polygenic disease characterized by abnormally high glucose levels in the blood; any of several metabolic disorders marked by excessive urination.

Identifying a master regulator gene for early embryonic development of the pancreas and other organs, scientists at Cincinnati Childrens Hospital Medical Center have moved a step closer to coaxing stem cells into pancreatic cells as a possible cure for type1 diabetes.

A commonly prescribed anti-diabetic drug can reduce an individuals risk of developing pancreatic cancer by 62 percent, according to a study.

A gene previously shown to be involved in the development of type 2 diabetes also predisposes children to having a lower birth weight, according to a study.

Low levels of Vitamin D are associated with diabetes.

Type 2 Diabetes

Research revealed that Type 2 Diabetes can be cured by consuming a low-calorie diet daily for four months. The study showed that people who cut down on their calories intake had a significant improvement in the condition.

Diabetes Studies and Research

In May 2012, a new study has revealed that a potent two-pronged attack on diabetes can cure it. The powerful combination therapy can tackle the condition even at a late stage.


  • As of 2012, around 370,000 Britons have Type 1 diabetes.

Diabetes in News

Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health
Business Wire IndiaFerring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions.

Bajaj Finserv launches LighterwithEMI campaign on World Obesity Day
Business Wire IndiaBajaj Finserv, through its lending arm, Bajaj Finance Ltd has announced a campaign #LighterwithEMI on World Obesity Day offering slimming treatments and fitness products on no-cost EMI

Concept Medical Inc. Raises INR 440 Crores for Investigational Device Exemption (IDE) for the World’s First Sirolimus-Coated Balloon
Business Wire IndiaDr. Kiran Patel – a Board-Certified cardiologistDr. Manish Doshi – Founder & Managing Director/Director of Envision Scientific and Concept MedicalConcept Medical Inc. (CMI) has approached the FDA for an Investigational Device Exemption (IDE) for their Sirolimus-Coated Balloon (DCB)

New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease
Business Wire India Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1

Merck Foundation Plans to Conduct 5th Edition of Merck Africa Asia Luminary in Dakar, Senegal
Business Wire IndiaFrom (L-R) H.E. First Lady of the Republic of Chad Madame Hinda Deby Itno; H.E. First Lady of the Republic of Niger Madame Aissata Issoufou Mahamadou Prof. Frank Stangenberg-Haverkamp, Chairman of the Executive Board of E. Merck KG; ; H.E. First Lady of the Republic of Guinea Madame Conde Djene; H.E. First Lady of Central African Republic H.E. Madame Brigitte Touadera; Dr

Boehringer Ingelheim and Lilly present full results of Trajenta®’s CARMELINA® cardiovascular outcome trial
Business Wire India Trajenta® demonstrated a similar long-term cardiovascular and kidney safety profile compared to placebo in adults with type 2 diabetes1 The results of CARMELINA® were presented at the 54th EASD Annual Meeting

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Business Wire India

Elbrit Life Sciences to Expand Its Domestic Footprint With a USD 3 Million Investment From Its Parent Firm Capital Investments
Business Wire IndiaElbrit Life Sciences has proudly announced that it is expanding its footprint in the domestic pharmaceutical industry. The fast-growing domestic pharmaceutical company is presently in advanced talks with its parent investment firm Capital Investments and a Qatar based investment firm to raise 3 million USD

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC
Business Wire India

WIPO and IFPMA Launch New Online Patent-Search Resource to Help Health Agencies Procure Medicines
Business Wire IndiaWIPO and the research-based pharmaceutical industry today launched a new online tool designed to help procurement agencies better understand the global patent status of medicines.

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
Business Wire India

175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis
Business Wire IndiaRoughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris

Zerovia Introduces Natural Sugar Substitute to Make Your Life Sweeter
Business Wire IndiaZerovia Natural Stevia SweetenerIn line with the vision to introduce products ingrained in wellness and health, Zerovia has introduced Stevia Natural Sweeteners in the Indian market. Zerovia Natural Sweeteners are zero calorie natural sugar substitutes made from the extracts of stevia

Merck Foundation to Underscore Their Long Term Commitment to Build Healthcare Capacity in Senegal
Business Wire IndiaDr. Rasha Kelej, CEO of Merck Foundation with His Excellency MACKY SALL, The President of SenegalDr. Rasha Kelej, CEO of Merck Foundation with Hon. Abdoulaye Diouf Sarr, Minister of Health of SenegalDr. Rasha Kelej, CEO of Merck Foundation during the WHO Regional Meeting for African Ministers of Health in DakarMessage from Dr

Frost & Sullivan’s GIL India 2018 Discussed Technology as a Key Differentiator and Embracing Change as a Force for Growth
Business Wire IndiaKiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Limited, honored with Frost & Sullivan's '2018 GIL Visionary Leadership Award' at GIL India 2018

As Flood Waters Start to Ebb in Kerala, Aster Volunteers Lend a Hand Round the Clock to Ensure Health and Hygiene for the Grieved

MetLife’s New Blockchain Health Insurance Product Eliminates Claims
Business Wire IndiaMetLife Asia’s Singapore-based innovation center, LumenLab, has begun testing the world’s first, automated insurance solution using blockchain technology to offer pregnant women financial protection in case of gestational diabetes, without ever needing to make a claim.

Boehringer Ingelheim: New sub-analyses to be presented at ESC Congress 2018 further support positive safety profile of Pradaxa® (dabigatran etexilate)
Business Wire India Nine sub-analyses from RE-DUAL PCI™ and GLORIA™-AF accepted for presentation at ESC Congress 2018; Data from both studies have led to positive update of the SmPC for Pradaxa® in the EU

Century Pai Foundation Takes a Step Towards Helping Channahalli Residents Live a Healthier Life
Business Wire IndiaMore than 600 villagers from Channahalli participated during the health check-up campSchool children during the Independence Day celebrations at Channahalli government school More than 600 villagers benefitted from complete health check-up camp. Doctors in attendance were general physicians, orthopedics, gynecologist, dentist, ophthalmologist and ENT specialist

MAHE Researchers Discover Biomolecules That Prevent Insulin Effects on Blood Vessels in Diabetic Individuals
Business Wire IndiaInsulin, a hormone secreted by the pancreas, plays an important role in stimulating the muscle, fat, and liver cells to consume glucose and produce energy. In addition to this, insulin also carries out specialized functions in cells such as the endothelial cells, which line the blood vessels throughout the body

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc

MintHealth Announces Vidamints (VIDA) to Align Stakeholders in a New Healthcare Ecosystem
Business Wire IndiaMintHealth™ offers a global decentralized health platform with a portable, secure, and self-sovereign personal health record (PHR) built on blockchain technology and designed to drive healthy patient behavior through the Vidamint™ token

24MRC Network Felicitated the Winners of 2017 Leaders Awards
Business Wire IndiaDr. Udit Raj (Honorable Member of Parliament & National Chairman of the All India Confederation of SC/ST Organizations) & Prof. (Dr.) J. D. Agarwal (Chairman – The Board of Governors & Sr

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma
Business Wire India

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
Business Wire IndiaNew data showed that empagliflozin reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease

Diabetic Patients must Stay Alert to Diabetic Retinopathy
Business Wire IndiaK.T. Rajan With the number of diabetic patients going up fast in the country, people need to be vigilant not just to cut down their chances of contracting it but also watch out for allied medical ailments if they already have this lifestyle-related medical condition

Sirona Biochem Announces SGLT2 IND Submission Milestone
VANCOUVER, BC--(Marketwired - December 29, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that partner Jiangsu Wanbang Biopharmaceuticals has confirmed an Investigational New Drug (IND) submission to China's Food and Drug Administration (CFDA) for its SGLT2 inhibitor

Vernalis and Servier Achieve Research Milestone
Vernalis PLC (LSE: VER)

Monster Digital, Inc. Provides Update Regarding Anticipated Closing Date for Merger with Innovate Biopharmaceuticals, Inc.
Monster Digital, Inc. (NASDAQ: MSDI) ("Monster Digital" or the "Company") announced today that the Company and Innovate Biopharmaceuticals, Inc. ("Innovate") have agreed to work towards the closing (the "Closing") of the proposed reverse merger ("Merger") between Monster Digital and Innovate on or before December 19, 2017.

Alimera Sciences to Present at the 10th Annual LD Micro Conference
Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 10th Annual LD Micro Conference, to be held December 5 - 7, 2017, at the Luxe Sunset Boulevard Hotel in Los Angeles, California

MetLife Hong Kong Sponsors Diabetes Management Activities
MetLife Hong Kong* sponsored diabetes management activities coinciding with World Diabetes Day in November. Joining hands with the Diabetic Support Group, MetLife Hong Kong held the Diabetes Management Educational Seminar to raise awareness of the rising trend of diabetes cases and their associated health risks. The seminar aimed to promote diseases prevention and management.

Future Farm and Rahan Meristem Form JV to Breed and Propagate Elite Clones of Cannabis and Secures $440,000 Investment
Future Farm Technologies Inc. (the "Company" or "Future Farm") (CSE: FFT) (OTCQB: FFRMF) is pleased to announce a new 50/50 joint venture (the "JV") between Future Farm and Rahan Meristem Ltd

Naia Rare Diseases Announces Clinical Trial Authorisation (CTA) to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome in the United Kingdom

Agritek Holdings, Inc. Announces Expansion Plans For Additional 900 Acres In Pueblo, Colorado For CBD Research Cultivation Farm And New Infused Products Agreement
Agritek Holdings, Inc. (OTCQB: AGTK), a fully integrated, active real estate investor for the cannabis sector and consultant for multiple cannabis brands today announced that the Company has agreed and entered into negotiations to purchase the surrounding nine-hundred (900) acres of its' existing 80 acre Hemp planned research site in Pueblo, Colorado.

Chester County Eye Doctors Bring Attention to Diabetic Retinopathy During American Diabetes Month
According to the American Diabetes Association®, approximately 1.5 million Americans are newly diagnosed with diabetes every year. November is American Diabetes Month®, an annual event designed to promote awareness of the disease's challenges

Zafgen Reports Third Quarter 2017 Financial Results
BOSTON, MA--(Marketwired - November 07, 2017) - Zafgen, Inc. (NASDAQ: ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by type 2 diabetes, rare diseases and other metabolic diseases, today announced its third quarter 2017 financial results.

VIVUS Reports Third Quarter 2017 Financial Results
CAMPBELL, CA--(Marketwired - November 07, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended September 30, 2017 and provided a business update.

Monster Digital, Inc. Announces Successful Stockholder Meeting
Monster Digital, Inc. (NASDAQ: MSDI) ("Monster" or the "Company") today announced its special meeting of stockholders held on November 9, 2017 went smoothly and all proposals were voted affirmatively and accepted. This included a proposal to adopt the Agreement and Plan of Merger and Reorganization with Innovate Biopharmaceuticals, Inc.

Corix's Unique Acquisition Paves the Way for Global Sales -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the ramifications of the recent acquisition of Pharmaceutical Development Corp. by Corix Bioscience Inc. (OTCQX: CXBS).

NanoVibronix Receives Health Canada Approval to Sell WoundShield(TM) in Canada
ELMSFORD, NY--(Marketwired - December 28, 2016) - NanoVibronix, Inc. (OTCQB: NAOV), a medical device company, today announced that it has received clearance to sell the WoundShield™ in Canada

2020 On-site Brings State-of-the-Art Mobile Vision Care Centers to Chicago Businesses
2020 On-site, the only company bringing state-of-the-art mobile vision centers on-site to businesses, announced today that it has expanded to Chicago, enabling employees to get a comprehensive eye exam at their place of work in 15 minutes. 2020 On-site is headquartered in Boston, where it serves 300+ corporate clients including Wayfair, Microsoft, Ocean Spray, Pfizer and Uber

RespireRx Pharmaceuticals Inc. Announces Positive Results from Phase 2B PACE Study Conducted by the University of Illinois Dronabinol Reduces Symptoms of Obstructive Sleep Apnea
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), is pleased to announce positive results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial conducted by Dr. David Carley and colleagues at the University of Illinois at Chicago and Northwestern University

Dr. Richard Liebowitz Named President of NewYork-Presbyterian Brooklyn Methodist Hospital
NEW YORK, NY--(Marketwired - December 20, 2016) - Dr. Richard Liebowitz has been appointed president of NewYork-Presbyterian Brooklyn Methodist Hospital, effective February 6. Currently NewYork-Presbyterian's chief medical officer, Dr. Liebowitz succeeds Mark Mundy, who announced his retirement earlier this year after more than two decades of leadership.

IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
MOUNTAIN VIEW, CA--(Marketwired - December 19, 2016) - Amunix is pleased to announce that Naia Rare Diseases, a biopharmaceutical company developing drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases, has announced submission of an Investigational New Drug (IND) application to the U.S

AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
LOUISVILLE, CO--(Marketwired - December 15, 2016) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has commenced an offer to amend (the "Offer to Amend") certain warrants to purchase 16,450,915 shares of AntriaBio common stock originally issued by AntriaBio

UPDATE - Geographic Variation in US Hospital Outcomes: The Closest Hospital May Not Always Be the Best
A pioneering study of over 22 million hospital admissions found significant variation in health outcomes across the United States. Patients in low-performing hospitals (bottom 10%) are three times more likely to die and 13 times more likely to experience complications than those in high-performing hospitals (top 10%).

Geographic Variation in US Hospital Outcomes: The Closest Hospital May Not Always Be the Best
A pioneering study of over 22 million hospital admissions found significant variation in health outcomes across the United States. Patients in low-performing hospitals (bottom 10%) are three times more likely to die and 13 times more likely to experience complications than those in high-performing hospitals (top 10%).

Cell MedX (CMXC) Widens Scope for Breakthrough Technology --, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing Cell MedX Corp

Proove Biosciences Launches Version 2.0 of Its One-Of-A-Kind Proove Pain Perception Profile
Proove Biosciences, Inc., the Healthcare Decision Company™, is announcing version 2.0 of its already successful Proove Pain Perception® Profile -- currently being used by hundreds of physicians on tens of thousands of patients around the country to objectively understand a patient's pain perception and recommend appropriate treatment

Dental Savings Plans May Be the Answer to the Oral Health Care Crisis
PLANTATION, FL--(Marketwired - December 12, 2016) - Lack of access to dental care has been identified as a growing public health care crisis, especially for those who are uninsured or under-insured. And those without dental benefits report higher incidences of illnesses that can severely impact their health and overall wellbeing.

5 Tips for Managing Diabetes
(Family Features) Living with diabetes is no laughing matter, but as many would say, laughter is often the best medicine.

Greengro Technologies, Inc. Fortifies Product Line with Modular Lab Rooms for Up and Coming Turn-Key Extraction Labs
Greengro Technologies, Inc. (OTC PINK: GRNH), a world-class provider of eco-friendly green technologies, announces today that it has purchased a 20 litre supercritical CO2 extraction machine for its all new turn key extraction labs. This system utilizes high-flow pumps and large capacity extraction columns to rapidly recover essential oils from various botanical sources.

Corbus Pharmaceuticals Announces Completion of Phase 2 Study of JBT-101 (Resunab) for the Treatment of Cystic Fibrosis
NORWOOD, MA--(Marketwired - December 29, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed its Phase 2 study evaluating JBT-101 ("Resunab") for the treatment of cystic fibrosis ("CF")

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data
Business Wire IndiaMylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the results of the HERITAGE study have been published in the Journal of the American Medical Association (JAMA)

Rs. 20/Day to Lose Weight Naturally, Less than the Cost of a Coffee
Business Wire IndiaGuduchi The Ayurvedism announced the nationwide release of Obesidat, India’s first scientifically proven research based Ayurvedic weight loss tablet on 11th of Nov 2016 and it’s been 45 days since then the positive feedbacks have been flowing in from 1000's of Obesidat users both nationally and internationally

Diabetes Care Goes Digital as RSSDI Partners with Wellthy Therapeutics
Business Wire IndiaThe Research Society for The Study of Diabetic in India (RSSDI) has partnered with Wellthy Therapeutics, a digital therapeutics company focused on improving diabetes care and outcomes through Artificial Intelligence. Wellthy Diabetes is an artificial intelligence powered diabetes health coach for patients and a virtual clinical assistant for doctors

CHMP adopts a positive opinion acknowledging that Jardiance® reduces the risk of CV death
Business Wire IndiaThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to update the Jardiance® (empagliflozin) label including a change to the indication statement

AIMIL Pharmaceuticals Wins AYUSH Brand of the Year
Business Wire IndiaFor its persistent commitment towards healthcare based on Ayurveda, AIMIL pharmaceuticals won the Gold Award in the AYUSH brand of the year category at the India Health & Wellness Summit and Awards 2016. AIMIL’s product BGR-34 was awarded silver under the Health Innovations category at the same awards

​Dr. Gregory Brammer -- Discusses Workplace Violence in the Emergency Department
NEW YORK, NY--(Marketwired - December 30, 2015) - Gregory Brammer, Expert Emergency Medicine Specialist and Fellow of the American College of Emergency Physicians, has recently brought awareness to the massive systemic problem of workplace violence in our nation's Emergency Departments (ED)

Full Tummy Tuck vs. Mini Tummy Tuck -- What's the Difference?
A tummy tuck, or "abdominoplasty," is one of the most commonly requested cosmetic surgery procedures today. After all, who would say no to a slimmer, flatter stomach? Tummy tucks help streamline the shape and do wonders for self-esteem. Dr

Orgenesis Note Holders Elect to Convert $950,000 of Outstanding Notes
Orgenesis Inc

Boston Therapeutics' sugardown(R) in Clinical Trials Reduces Glucose, Fructose and Insulin
Boston Therapeutics, Inc. (OTCQB: BTHE) released final trial results from its proof of concept (POC) Sydney University study that showed consumption of sugardown® tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a favorable response

Dr. Gregory Brammer -- Supports Expanded Point-of-Care Testing in the Pre-Hospital Arena
NEW YORK, NY--(Marketwired - December 23, 2015) - Renowned Emergency Medicine Expert Physician Dr. Gregory Brammer has voiced his opinion regarding Point-of-Care-Testing (POCT) and the 2014 EMSWORLD article entitled "WHAT'S THE POINT of Point-of-Care Testing", where the vast potential of POCT was extolled

Liberator Medical Announces Definitive Settlement of Qui Tam Litigation
STUART, FL--(Marketwired - December 22, 2015) - Liberator Medical Holdings, Inc. ("Liberator") (NYSE MKT: LBMH), a leading national direct-to-consumer provider of quality medical supplies through its subsidiary, Liberator Medical Supply, Inc., today announced that it has entered into a definitive settlement with the U.S

Flamel Technologies Announces Positive Interim Results of a First-in-Man Clinical Trial With Medusa(TM) Exenatide
Flamel Technologies (NASDAQ: FLML) today announced positive interim results from a Phase 1a clinical trial in healthy volunteers of a once weekly subcutaneous injection formulation of exenatide using its proprietary Medusa™ technology (FT228). The study achieved all safety and pharmacokinetic (PK) assessment objectives throughout ascending single dose administrations of FT228

Zivo Bioscience Subsidiary, WellMetris LLC, Concludes Production Run of Human Wellness Testing Assays, Begins Validation
ZIVO Bioscience, Inc. (OTCQB: ZIVO), announces today that its wholly-owned subsidiary, WellMetris LLC, has successfully concluded manufacturing runs of assays for its proprietary, patent-pending metabolic testing panel for human application. The manufacturing run completes the full wellness panel with the latest assay formulations.

Biodel Reports Fourth Quarter and Fiscal Year 2015 Financial Results
DANBURY, CT--(Marketwired - December 17, 2015) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the fourth fiscal quarter and year-ended September 30, 2015

Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes
Bagsværd, Denmark, 17 December 2015 - Novo Nordisk today announced the headline results from the fourth phase 3a trial for semaglutide, SUSTAIN2. Semaglutide is a new GLP-1 analogue administered subcutaneously once weekly. The double-blinded trial investigated the efficacy and safety of 0.5 mg and 1

Dr. Gregory Brammer -- Brings Awareness to the New Diabetes Drug INVOKANA
NEW YORK, NY--(Marketwired - December 16, 2015) - Expert Emergency Medicine Specialist and Fellow of the American College of Emergency Physicians, Dr. Gregory Brammer has recently brought awareness to the potential dangers of the new diabetes drug INVOKANA (canagliflozin)

Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
HERCULES, CA--(Marketwired - December 16, 2015) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced that its D-100™ System for A1c testing has obtained clearance from the U.S

Orgenesis Secures $10 Million in Financing and Retains Ownership of MaSTherCell SA
Orgenesis Inc

L-Arginine -- A Good Tool in the Fight to Prevent Stroke
AMERICAN FORK, UT--(Marketwired - December 15, 2015) - Numerous studies indicate that the ingredients in the popular health supplement L-arginine Plus® may contribute to the prevention of stroke among adults. It may also play a role in the reduction of cholesterol levels, and the improvement of blood pressure, both of which contribute to helping combat heart disease.

Give the Gift of Sight
(Family Features) This holiday, give a gift that changes the way someone you care about sees the world -- a gift that keeps giving even after the holidays are over.

Solera Health Partners With Blue Mesa Health to Deliver Innovative Digital Program for Diabetes Prevention
Solera Health, Inc., a technology-enabled health community integrator for evidence-based chronic disease prevention, today announced that it has partnered with Blue Mesa Health, a digital therapeutics platform for chronic disease prevention, to deliver an innovative new digital National Diabetes Prevention Program (DPP) to help combat the diabetes epidemic

Iran's Pharmaceutical Sector to Become a Pharma Powerhouse Post Sanction Era - Biotechnology Sector to Have Lucrative Opportunities
Business Wire IndiaWith annual consumption of 30 billion units of various generic medicines, Iran, the second-biggest consumer of generics in the Asian continent spent over USD 4.5 billion on drugs in 2015

Biocon Introduces CIMIVIR-L™ for Hepatitis-C in India
Business Wire IndiaBiocon Ltd, Asia's premier biotechnology company, today announced the introduction of an advanced novel therapy CIMIVIR-L™ for the treatment of Hepatitis C in India. CIMIVIR-L™ is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of  the innovator product commercialized by Gilead Sciences in the US

Award Winning Leader and Author Dr Prem Publishes Guides to Medical Tourism and Wellness Tourism
Business Wire IndiaRising global health awareness with people seeking better and convenient avenues of healthcare and wellness has led to the creation of niche wellness and medical tourism sectors, two flourishing domains in the global tourism industry

Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
Business Wire IndiaSanofi and Boehringer Ingelheim today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transaction would consist of an exchange of Sanofi animal health business (“Merial”) with an enterprise value of €11

Cell MedX Corp. (CMXC) Announces Change of Auditors
Cell MedX Corp. (OTCBB: CMXC), (the "Company") announces that the Company has appointed Dale Matheson Carr-Hilton LaBonte LLP Chartered Accountants as its new independent auditors replacing Sadler, Gibb & Associates, LLC

Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity
Bagsværd, Denmark, 23 December 2014 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity

South Dakota Based Mitogenetics Revolutionizes How People Manage Diseases
Mitogenetics, a biomedical technology firm with strong South Dakota roots, in partnership with the State University of New York, is developing technology to regulate the action of mitochondria

Mitogenetics Revolutionizes How People Manage Diseases
Mitogenetics, a biomedical technology firm in partnership with the State University of New York, is developing technology to regulate the action of mitochondria

Stevia Corp. Confirms Protocol to Produce Synthetic CBD
Stevia Corp

Cell MedX Corp. (CMXC) Announces the First Order Received by Its Newly Formed Wholly Owned Subsidiary
Cell MedX Corp. (OTCBB: CMXC) (the "Company") is pleased to announce the formation of its wholly owned subsidiary, Avyonce Cosmedics Inc. ("Avyonce"). Avyonce will concentrate its efforts on the resale and marketing of spa technology and equipment to the worldwide beauty and wellness industry. Avyonce has received its first order for approximately US$55,000 from Dubai, United Arab Emirates.

Biodel Reports Fourth Quarter Fiscal Year 2014 Financial Results
DANBURY, CT--(Marketwired - December 17, 2014) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2014.

Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000
Addex Therapeutics /Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

ETST, an Emerging Health and Wellness Company, Adds Attorney, Steven Warm, Esq., to the Advisory Board to Assist With Its New Cutting Edge Nutritional Products, Dietary Supplements and All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil Products
BOCA RATON, FL--(Marketwired - December 16, 2014) - Earth Science Tech, Inc. (OTCQB: ETST) ("ETST" or "the Company"), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, today announced the addition of Steven Warm, Esq. to its advisory board.

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Novartis International AG /Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Liberator Medical Reports Revenue of $74.5 Million for Its Fiscal Year Ended September 30, 2014
STUART, FL--(Marketwired - December 15, 2014) - Liberator Medical Holdings, Inc. (NYSE MKT: LBMH) today announced the financial results for its fiscal year ended September 30, 2014. Financial highlights are summarized below:

VIVUS Announces Favorable Formulary Positioning for Qsymia
MOUNTAIN VIEW, CA--(Marketwired - December 15, 2014) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today announced that Qsymia is the sole anti-obesity agent listed on the CVS/Caremark Performance Drug List, or PDL

Experts Say Parents Play a Key Role in Childhood Tooth Decay Prevention
WASHINGTON, DC--(Marketwired - December 12, 2014) - By mid-afternoon, Heather Hereford is exhausted. With a set of twins and a son all under the age of 4, running on four hours of sleep isn't unusual.

Biodel to Report Fourth Quarter Fiscal Year 2014 Financial Results on December 17, 2014
DANBURY, CT--(Marketwired - December 10, 2014) - Biodel Inc. (NASDAQ: BIOD) will issue its fourth quarter fiscal year 2014 financial results on Wednesday, December 17, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that the U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for BTI-320 to treat Type 2 diabetes and weight management

New Management of Biostem Technologies (BSEM) Announces Name and Symbol Change to Be in Effect Today; BSEM Also Moves Forward to Complete an Interactive Webpage and Will Be Attending the 22nd Annual World Congress on Anti-Aging Medicine Dec 11-13, 2014
OAKLAND PARK, FL--(Marketwired - December 09, 2014) - Biostem Technologies, Inc. (OTC PINK: BSEM) (BSEM), is pleased to announce the Financial Industry Regulatory Agency (FINRA) has approved a name and symbol change from Caribbean International Holdings, Inc. to Biostem Technologies, Inc. (BSEM) effective today. The new management believes this name will reflect Biostem Technologies, Inc

Omni Bio Announces Encouraging Clinical Data for Use of Alpha-1 Antitrypsin (AAT) in Steroid-Resistant Graft Versus Host Disease
Omni Bio Pharmaceutical, Inc

Ossianix Expands and Extends Its Research Collaboration with Lundbeck on CNS Therapeutics
Ossianix, Inc. has announced an expansion and extension of its strategic research collaboration with H. Lundbeck A/S (Lundbeck). This collaboration follows a previous equity investment in 2012 and prior research collaboration in 2013

A New Era Comes When Diabetes Can Be Treated Basically Using Cells of Pancreas
STC Stem Cell Treatment & Research Institute ( of STC Life Co., Ltd. (Chairman: Kye Ho Lee) succeeded in differentiating new pluripotent stem cells without side effect into beta-cells that control insulin in pancreas, after conducting research projects for several years

Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Seattle Genetics, Inc

US Equity Holdings CEO Joins Buck Advisory Council
Chester Aldridge, Chairman and CEO of US Equity Holdings, has joined the Buck Institute's Buck Advisory Council (BAC). The long-time Marin resident will take an active role in advising the Institute on the commercialization of some of its most promising research assets Launches Estrodetox
Can the use of marijuana cause man b**bs? According to an article Dr. Anthony Youn, a plastic surgeon from Detroit, wrote for CNN earlier this month, it can. The reason behind it is the drug's effect on hormone levels, causing an imbalance between testosterone and estrogen

Liberator Medical Reports Revenue of $69 Million for Its Fiscal Year Ended September 30, 2013
Liberator Medical Holdings, Inc. (NYSE MKT: LBMH) today announced the financial results for its fiscal year ended September 30, 2013. Financial highlights are summarized below:

Viridian Health Management Releases Year-End Wrap-Up of Product Launches, Initiatives, Leadership and Publications
PHOENIX, AZ--(Marketwired - December 20, 2013) - Viridian Health Management, a value-driven health improvement company focused on powering performance in population health, today released a year-end wrap-up and preview of activities for 2014.

Jafari Facebook Contest Brings Sugar-Free Dessert Recipes to Diabetics
Drawing on their deep knowledge and understanding of the challenges diabetics face when it comes to diet, Jafari Medical Supply recently sponsored a Facebook contest with the goal of collecting diabetic-friendly dessert recipes

Parks Associates: Networked Medical Devices to Exceed 14 Million Unit Sales in 2018
New digital health research from Parks Associates predicts U.S. unit sales of networked medical devices will exceed 14 million units by 2018, more than five times the sales from 2012

ANORO(TM) ELLIPTA(TM) Approved as First Once-Daily Dual Bronchodilator for the Treatment of COPD in the US
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc

Orgenesis Secures $3 Million in Funding From Kodiak Capital Group
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has entered into a $3 million common stock purchase agreement with Kodiak Capital Group LLC, a Newport Beach, Calif.-based institutional investor.

Nuvilex's Medical Marijuana Research Could Use Cell Encapsulation Technology to Address Brain Cancers
The executives at Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., had to take note of recent results released in a marijuana study done by a group of researchers in Spain. The study used a type of encapsulation to inhibit brain cancer cell growth in mice

Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)

It's Not Too Late to Vaccinate -- Get Your Flu Vaccine Today
WASHINGTON, DC--(Marketwired - December 10, 2013) - "Flu season typically peaks in February and can last as late as May," says Dr. Anne Schuchat, Assistant Surgeon General of the U.S. Public Health Service and Director of CDC's National Center for Immunization and Respiratory Diseases. "We are encouraging people who have not yet been vaccinated this season to get vaccinated now."

A Delicious Approach to Weight Loss, Healthy Eating
(Family Features) Weight loss tops the to-do list for many of us, especially at this time of year when thoughts turn to the holidays, resolutions, vacation and even the looming swimsuit season.

Insulet Announces Commercial Agreement With Amgen
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc., the world's leading independent biotechnology company, for a five year commercial agreement to supply Amgen with a delivery device specifically designed around the unique delivery needs of biotechnology medicines.

Metabolex Undergoes Capital Restructure and Renames as CymaBay Therapeutics
HAYWARD, CA--(Marketwired - December 10, 2013) - CymaBay Therapeutics, Inc., a biopharmaceutical company formerly known as Metabolex, has recently completed a capital restructuring. CymaBay will focus exclusively on advancing its clinical portfolio which consists of three compounds in Phase 2 clinical development that are designed to address unmet medical needs in the metabolic disease space

Boston Therapeutics Appoints Three to Management Positions
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Edward Shea as Vice President Business Development, Tina M. Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager, effective immediately.

GSK and Theravance Announce Positive Results From Pivotal Phase III Study for Fluticasone Furoate/Vilanterol in Asthma
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate "FF"/vilanterol "VI" designed to support a potential filing for an asthma indication for adults in the US.

After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment
Eli Lilly & Co. (LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced, inoperable pancreatic cancer back in 1996. Meanwhile, Nuvilex, Inc. (OTCQB: NVLX) has its eyes on a piece of that billion dollar pie with the company's live-cell encapsulation based treatment for pancreatic cancer

Historic 6th Annual Pharmaceutical Leadership Summit and Pharmaleaders Awards 2013 Focused to Give Aam Admi of India Affordable Medicines and Quality Healthcare
In a sequel to the sixty days of the voting by the Indian masses to select the best of the best in the final five nominees in various important categories & individual nonvoting categories, Pharmaleaders (www.pharmaleaders

Noted Healthcare Industry Experts and Medical Professionals to Receive Pharmaleaders 2013 Power Brand Awards
In an era where Healthcare in India is the most neglected as Politicians & Policy Makers are busy scoring their political points, Pharmaleaders attempt to raise the uncomfortable questions ignored by other media houses as we believe that healthcare is key to the nation development & India cannot be a mute spectator where policy reforms in healthcare has taken a backstage over political issues

Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Seattle Genetics, Inc

ALR Technologies Announces Election of New Board Member and Appointment of Chief Commercial Officer
ALR Technologies Inc. (OTCBB: ALRT) (the "Company"), a health information technology developer, is pleased to announce the election of William S. Smith to the Board of Directors and the appointment of Mr. Smith as Chief Commercial Officer, effective January 1, reporting to CEO Sidney Chan. Mr

2013 Could Be "The Year of The Point of Care Test": Kalorama
A number of developments bode well for tests that are performed in the healthcare settings, according to Kalorama information. The healthcare market research publisher said that the nearly $17 billion point of care test (POCT) market will see faster revenue growth in 2013 than tests sent to central labs for processing

GoHealth: Affordable Care Act Changes in 2013
GoHealthInsurance, the leading online exchange for individuals and families to compare health insurance quotes, wants consumers to know how the Affordable Care Act (ACA) will affect health care in 2013. Americans will see important changes occur in health care programs and the way they can deduct medical expenses.

Western Diabetes Institute Shares Expertise in Response to Student's Death From Undiagnosed Diabetes
The tragic death of Fremont Academy of Engineering and Design 11th grade student Nikita Rodriguez from undiagnosed diabetes in late November 2012 was not in vain.

ActiveCare Announces Expansion of Customer Contract With Southern Benefit Services, LLC
ActiveCare, Inc. (OTCBB: ACAR), the service leader in disease and diabetes management, today reported the expansion of its customer contract with Southern Benefit Services, LLC. Through this contract, ActiveCare has added over 1,000 new members in the past 9 months with annualized revenues in excess of $1.2 million

Omni Bio Pharmaceutical Appoints New CEO
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr

Boston Therapeutics Approved in France to Initiate a Clinical Trial With SUGARDOWN(R) in Patients With Type II Diabetes
Boston Therapeutics, Inc

APMA and Neuropathy Action Foundation Team Up With Jerry Mathers to Raise Awareness
The American Podiatric Medical Association (APMA), the nation's leading professional organization for podiatrists, and Neuropathy Action Foundation (NAF), the premier patient advocacy organization for neuropathy education, have joined together to produce an educational video focusing on diabetic peripheral neuropathy featuring celebrity Jerry Mathers from the hit sitcom "Leave It to Beaver."

Medecision Awarded Full NCQA Disease Management Systems Certification
Medecision, the leader in collaborative healthcare management technology, today announced that it has earned National Committee for Quality Assurance (NCQA) Disease Management Systems Certification for the full suite of Aerial™ solutions including Disease Management (DM) Clinical Programs.

Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2 diabetes
Poxel S.A. /Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2 diabetes . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

How to Love Your Heart
(Family Features) It beats about 100,000 times a day, 35 million times a year. It pumps blood through the body three times every minute, taking that blood on the equivalent of a 12,000 mile trek every 24 hours. Even at rest, it works twice as hard as the leg muscles of a person running. The heart is a remarkable, vital muscle that warrants great care and maintenance

GCS-100 Demonstrates Statistically Significant Reduction in Liver Fibrosis
La Jolla Pharmaceutical Company (OTCQB: LJPC) (the "Company" and "La Jolla"), a leader in the development of therapeutics that target galectin-3, announced today the results of a mouse study examining the effect of GCS-100 on liver fibrosis

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
Novartis International AG /Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Eye Health and Vision Care Should Be Essential Covered Services Offered by Health Plans
Americans would benefit from having all health plans cover vision exams as part of their standard benefit according to a new study in the Archives of Ophthalmology, published December 10, 2012

Next-Generation OmniPod(R) Insulin Pump Cleared by FDA
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology, today announced that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next-generation OmniPod® Insulin Management System

eMarketer Expands Coverage of Industry Verticals
eMarketer announced today that it will significantly expand its coverage of several major verticals to meet growing demand from eMarketer clients focused on those industries.

VisualMED and Intelaform Expand Partnership to Address Hospital Readmission Reduction Transition Care Programs in National Capital Region
VisualMED Clinical Solutions Corp. ("VisualMED") (PINKSHEETS: VMCS) (FRANKFURT: VA6) and Intelaform, Inc. ("Intelaform") announce an expansion of their Maryland transitional care initiative to include the District of Columbia by forming the National Capital Region Hospital Readmission Reduction Consortium ("NCR Consortium")

New Quintiles Resource for Cancer Patients Wins Third Health Award for
Cancer patients looking for clinical trials of oncology therapies in their own areas plus information and news to help them understand the disease and its treatments have a valuable new online resource at The Quintiles-created site has now been recognized with its third Web Health Award in as many years.

Heartbeat Experts Expands Pharmaceutical Clients in Emerging Markets
Heartbeat Experts, the global leader in stakeholder management solutions for the life sciences industry, announced today increased revenue and expanded clients across Brazil, Russia, China, India and Korea. Heartbeat Experts’ reported combined revenue from these markets grew 50% in the third quarter of 2012.

Pathway Genomics Partners with Medcan Clinic, the Largest Private Health Care Clinic in Canada
Pathway Genomics Corporation, a San Diego-based clinical laboratory that offers clinical genetic testing services internationally, has partnered with the Medcan Clinic, Canada’s largest private health care clinic.

Regarding meat as 'treat' may help tackle obesity
One should only eat meat on feast days to help tackle obesity, a government food advisor has advised.

3 cups of black tea a day can cut heart attack risk by 60pc
Drinking just three cups of black tea a day can slash the risk of a heart attack by 60 per cent and dramatically reduce the threat of diabetes, experts say.

1 in 5 elderly people overindulging in alcohol
Boredom and loneliness in the post retirement phase is paving way for more and more older people to binge on alcohol beyond recommended levels, a new study has revealed.

ARI Recognized as an American Heart Association Platinum-Level Start! Fit-Friendly Company
ARI®, a leading global vehicle fleet management provider specializing in complex car and truck fleet programs, has been recognized as a Platinum-Level Start! Fit-Friendly Company by the American Heart Association's Start! initiative for helping employees eat better and engage in more physical activities.

Holman Automotive Recognized by American Heart Association as Worksite Fitness Innovation Company of 2011
Holman Automotive Group, one of the nation's top auto dealership and leasing companies, has been recognized by the American Heart Association as one of two Worksite Fitness Innovation Companies of 2011. The Biannual award is given to companies that develop and implement innovative and effective programs to promote physical activity in the workplace

Pacific Biomarkers Announces the Appointment of Amar A. Sethi, MD, PhD as Its New Chief Scientific Officer
Pacific Biomarkers (PBI), a Seattle, WA-based limited liability company that provides premier biomarker and specialty efficacy testing services to the drug development industry, has named the company's current Vice President, Research and Development, Amar A. Sethi, MD, PhD, as the new Chief Scientific Officer effective January 1, 2012. Dr

Boston Therapeutics Elects Dr. Henry Esber to Its Board of Directors
Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the election of Dr. Henry J. Esber to its Board of Directors, effective December 20, 2011.

Sugar free strawberries cultivated in Uttarakhand
Farmers in Ramnagar in Uttarakhand's Nainital District have taken up sugar free strawberry cultivation with an aim to ensure that the patients suffering from diabetes are able to consume it.

Brain cell malfunction linked to schizophrenia
Defect in certain portions of protein that package DNA is the root cause of Schizophrenia and the deficit is especially pronounced in younger people, a new study has suggested.

Is poor diet of shift workers a new form of occupational hazard?
The poor diet of shift workers should be considered as a new occupational health hazard, a new study has claimed.

Comment on this story